QS Investors’s Sage Therapeutics SAGE Stock Holding History

QS Investors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$4.55M	Hold	80,090	–	–	0.05%	248
2021 Q1	$6M	Buy	80,090 +74,590	+1,356%	+$6.12M	0.07%	210
2020 Q4	$476K	Hold	5,500	–	–	0.01%	805
2020 Q3	$337K	Sell	5,500 -19,350	-78%	-$981K	﹤0.01%	880
2020 Q2	$1.03M	Buy	24,850 +23,250	+1,453%	+$844K	0.01%	712
2020 Q1	$46K	Hold	1,600	–	–	﹤0.01%	1419
2019 Q4	$118K	Hold	1,600	–	–	﹤0.01%	1338
2019 Q3	$225K	Hold	1,600	–	–	﹤0.01%	1175
2019 Q2	$293K	Hold	1,600	–	–	﹤0.01%	1118
2019 Q1	$255K	Sell	1,600 -5	-0.3%	-$724	﹤0.01%	1149
2018 Q4	$154K	Hold	1,605	–	–	﹤0.01%	1212
2018 Q3	$227K	Hold	1,605	–	–	﹤0.01%	1171
2018 Q2	$251K	Buy	1,605 +800	+99%	+$126K	﹤0.01%	1133
2018 Q1	$130K	Hold	805	–	–	﹤0.01%	1315
2017 Q4	$133K	Buy	805 +5	+0.6%	+$485	﹤0.01%	1332
2017 Q3	$50K	Hold	800	–	–	﹤0.01%	1527
2017 Q2	$64K	Hold	800	–	–	﹤0.01%	1460
2017 Q1	$57K	Buy	+800	New	+$46.9K	﹤0.01%	1483

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

QS Investors's SAGE Position: Q2 2021 in Review

QS Investors held its Sage Therapeutics (SAGE) position steady in Q2 2021 at 80,090 shares worth $4.55M. The position accounts for 0.05% of the portfolio, ranked #248.

QS Investors first reported a position in SAGE in Q1 2017 and has held it in 18 quarters since. The position peaked at $6M in Q1 2021. 257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

QS Investors held 80,090 shares of Sage Therapeutics worth $4.55M as of Q2 2021.
QS Investors left its Sage Therapeutics share count unchanged in Q2 2021.
Sage Therapeutics made up 0.05% of QS Investors's portfolio in Q2 2021, its #248 holding.
QS Investors first reported a position in Sage Therapeutics in Q1 2017 and has held it in 18 quarters since.
QS Investors's Sage Therapeutics position peaked at $6M in Q1 2021.
257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.